Phathom Pharmaceuticals (PHAT) to Release Earnings on Thursday

Key Points

• Phathom Pharmaceuticals (NASDAQ:PHAT) is scheduled to release its Q2 2025 earnings on Thursday, August 7th, with analysts predicting a loss of ($0.76) per share and revenue of $35.58 million.
• AQR Capital Management recently increased its stake in Phathom Pharmaceuticals by 508.2%, indicating growing institutional interest as 99.01% of the stock is owned by institutional investors and hedge funds.
• Analysts have mixed ratings on the stock, with price targets ranging from $5.00 to $28.00, creating an average target price of $17.50 and a consensus rating of "Buy."

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.76) per share and revenue of $35.58 million for the quarter.

Phathom Pharmaceuticals Stock Performance

PHAT traded down $0.19 during mid-day trading on Friday, reaching $8.35. 501,927 shares of the stock were exchanged, compared to its average volume of 911,990. The stock has a market capitalization of $582.91 million, a PE ratio of -1.59 and a beta of 0.45. The company has a 50 day moving average price of $8.33 and a two-hundred day moving average price of $6.21. Phathom Pharmaceuticals has a 1 year low of $2.21 and a 1 year high of $19.71.

Hedge Funds Weigh In On Phathom Pharmaceuticals

An institutional investor recently raised its position in Phathom Pharmaceuticals stock. AQR Capital Management LLC boosted its position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 508.2% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 107,399 shares of the company's stock after acquiring an additional 89,741 shares during the period. AQR Capital Management LLC owned 0.15% of Phathom Pharmaceuticals worth $673,000 as of its most recent SEC filing. Institutional investors own 99.01% of the company's stock.

Wall Street Analyst Weigh In

PHAT has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Phathom Pharmaceuticals in a report on Monday, June 9th. Craig Hallum lifted their price objective on shares of Phathom Pharmaceuticals from $12.00 to $17.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Needham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, June 6th. Guggenheim lowered their target price on Phathom Pharmaceuticals from $18.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, The Goldman Sachs Group lowered their target price on Phathom Pharmaceuticals from $10.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $17.50.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.